Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating activities:
Loss for the year	$ (49,254,817)	$ (88,305,928)
Adjusted for:
Amortization	66,192	1,358,212
Depreciation	2,703,186	3,510,611
Operating lease expense	7,941,831	6,511,921
Interest expense	12,048,071	5,979,829
Interest income	(231)	(12,250)
Share-based compensation	726,679	347,787
Loss (gain) on extinguishment of loan	14,274	2,331,917
Loss on settlements (note 12(d) and 12(e))	3,295,904
Credit facility amendment fee (note 10(a))	1,000,000
Neuronetics Note non-cash financing costs (note 10(a))	116,356
Gain on lender warrants (note 12(a))	(6,567)	(38,430)
(Gain) loss on deferred share units (note 12(b))	(201,495)	372,724
Gain on performance share units (note 12(c))	(43,706)	(53,100)
Impairment loss (note 7)	285,390	45,834,688
Change in non-cash operating working capital:
Accounts receivable	(220,997)	3,105,826
Prepaid expenses and other	(559,109)	196,097
Advance for research collaboration (note 14)	1,300,000
Other payables	(3,475,000)
Accounts payable and accrued liabilities	3,605,174	5,610,578
Interest paid	(7,221,240)	(4,839,280)
Interest received	231	12,250
Payment of operating lease liabilities	(8,032,848)	(6,105,387)
Operating activities	(35,912,722)	(24,181,935)
Financing activities:
Net proceeds on issuance of common shares (note 15)	6,620,699
Finance costs incurred (note 10(a))	(984,709)	(3,074,459)
Bank loans advanced	26,731,638	55,000,000
Bank loans repaid (note 10(a))	(152,627)	(30,766,513)
Promissory notes advanced (note 10(a) and note 11)	9,695,000
Promissory notes repaid (note 10(a))	(800,000)
Principal repayment of finance lease liabilities	(3,419,265)	(5,896,579)
Non-controlling interest loans advanced	8,526	8,922
Non-controlling interest loans repaid	(24,000)
Distribution to non-controlling interest	(46,950)	(320,250)
Financing activities	37,628,312	14,951,121
Investing activities:
Acquisition, net of cash acquired		688,958
Change in restricted cash		250,000
Acquisition of subsidiary non-controlling interest (note 24)	(513)	(500,000)
Deferred and contingent consideration paid (note 13)		(250,000)
Purchase of property, plant and equipment	(15,326)	(33,866)
Investing activities	(15,839)	155,092
Increase (decrease) in cash	1,699,751	(9,075,722)
Cash, beginning of the year	1,623,957	10,699,679
Cash, end of the year	$ 3,323,708	$ 1,623,957